Oxaliplatin pharmacokinetics and pharmacodynamics in adult cancer patients with impaired renal function Journal Article

Authors: Takimoto, C. H.; Graham, M. A.; Lockwood, G.; Ng, C. M.; Goetz, A.; Greenslade, D.; Remick, S. C.; Sharma, S.; Mani, S.; Ramanathan, R. K.; Synold, T. W.; Doroshow, J. H.; Hamilton, A.; Mulkerin, D. L.; Ivy, P.; Egorin, M. J.; Grem, J. L.
Article Title: Oxaliplatin pharmacokinetics and pharmacodynamics in adult cancer patients with impaired renal function
Abstract: Purpose: To characterize the pharmacokinetics and pharmacodynamics of oxaliplatin in cancer patients with impaired renal function. Experimental Design: Thirty-four patients were stratified by 24-h urinary creatinine clearance (CrCL) into four renal dysfunction groups: group A (control, CrCL, ≥60 mL/min), B (mild, CrCL, 40-59mL/min), C (moderate, CrCL, 20-39mL/min), and D (severe, CrCL, <20 mL/min). Patients were treated with 60 to 130 mg/m2 oxaliplatin infused over 2 h every 3 weeks. Pharmacokinetic monitoring of platinumin plasma, plasma ultrafiltrates, and urine was done during cycles 1 and 2. Results: Plasma ultrafiltrate platinum clearance strongly correlated with CrCL (r2 = 0.712). Platinum elimination from plasma was triphasic, and maximal platinum concentrations (Cmax) were consistent across all renal impairment groups. However, only the β-half-life was significantly prolonged by renal impairment, with values of 14.0 ± 4.3, 20.3 ± 17.7, 29.2 ± 29.6, and 68.1h in groups A, B, C, and D, respectively (P = 0.002). At a dose level of 130 mg/m 2, the area under the concentration time curve increased in with the degree of renal impairment, with values of 16.4 ± 5.03, 39.7 ± 11.5, and 44.6 ± 14.6 Ag μh/mL, in groups A, B, and C, respectively. However, there was no increase in pharmacodynamic drug-related toxicities. Estimated CrCL using the Cockcroft-Gault method approximated the measured 24-h urinary CrCL (mean prediction error, -5.0 mL/min). Conclusions: Oxaliplatin pharmacokinetics are altered in patients with renal impairment, but a corresponding increase in oxaliplatin-related toxicities is not observed. © 2007 American Association for Cancer Research.
Keywords: adult; clinical article; controlled study; aged; aged, 80 and over; middle aged; clinical trial; solid tumor; antineoplastic agents; cancer patient; neoplasms; controlled clinical trial; pharmacodynamics; kidney disease; thrombocytopenia; creatinine; dose-response relationship, drug; creatinine urine level; platinum; urine; drug half life; oxaliplatin; organoplatinum compounds; plasma; creatinine clearance; drug elimination; kidney diseases
Journal Title: Clinical Cancer Research
Volume: 13
Issue: 16
ISSN: 1078-0432
Publisher: American Association for Cancer Research  
Date Published: 2007-08-15
Start Page: 4832
End Page: 4839
Language: English
DOI: 10.1158/1078-0432.ccr-07-0475
PUBMED: 17699862
PROVIDER: scopus
Notes: --- - "Cited By (since 1996): 19" - "Export Date: 17 November 2011" - "CODEN: CCREF" - "Source: Scopus"
Citation Impact
MSK Authors
  1. Sunil Sharma
    26 Sharma
  2. Shruti Sharma
    1 Sharma